Compare KLA Corp. (KLAC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Travere Therapeutics Inc. Common Stock — how do they compare? KLA Corp. trades at $177.51 (market cap $240.12B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: KLA Corp. is far larger — about 49.2× Travere Therapeutics Inc. Common Stock's market cap, and KLA Corp. pays a 0.5% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KLAC | TVTX | |
|---|---|---|
Market Cap | $240.12B | $4.88B |
Volume | 10,439,404 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $301.71 | $67.52 |
52-Week Low | $108.70 | $26.79 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $241.37B | $5.01B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $178.81, down 5.95% on the day, amid a broader tech selloff. The stock maintains a bullish technical signal, with strong fundamentals including a 35.57% net income margin and consistent earnings beats. Revenue reached $12.16B in 2025, with a robust backlog of $12.57B driven by AI demand, positioning the company for growth in semiconductor equipment.
The outlook remains positive with a consensus price target of $223.88, implying significant upside. Risks include competitive pressures from Applied Materials and ASML, and sensitivity to semiconductor capex cycles. Analyst sentiment is strongly bullish, with 28 buy ratings, supporting a favorable long-term investment case despite near-term volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
